Skip to main content
Erschienen in: Journal of Neuro-Oncology 1/2011

01.01.2011 | Laboratory Investigation - Human/Animal Tissue

Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells

verfasst von: Daisuke Muta, Keishi Makino, Hideo Nakamura, Shigetoshi Yano, Mareina Kudo, Jun-ichi Kuratsu

Erschienen in: Journal of Neuro-Oncology | Ausgabe 1/2011

Einloggen, um Zugang zu erhalten

Abstract

The mRNA cap-binding protein eukaryotic initiation factor 4E (eIF4E) plays an important role in mRNA translation; its activity is implicated in cell growth and proliferation. In experimental models, eIF4E over-expression induces cellular transformation, tumorigenesis, and lymphomagenesis. The activity of eIF4E is regulated by the Akt/mTOR and MAPK/MAP kinase-interacting kinase-1 (MNK1) pathways. While investigating the participation of the MNK1/eIF4E signaling pathway in primary central nervous system lymphoma (PCNSL), we noted the over-expression of eIF4E and phosphorylated eIF4E (p-eIF4E) in specimens from PCNSL patients. Western blot analysis using B-cell lymphoma cell lines showed that eIF4E phosphorylation was serum-independent and was selectively inhibited by the MNK1 inhibitor. Furthermore, MNK1 inhibitor led to reduced cyclin D1 expression and caused inhibition of cell proliferation and cell death in human brain malignant lymphoma cell line (HKBML). Also, the growth of the subcutaneous HKBML xenografts in mice was inhibited by intraperitoneal administration of MNK1 inhibitor compared with mice treated with vehicle (P = 0.026). Our data suggest that in PCNSL cells eIF4E phosphorylation plays an important role in proliferation and our results identify inhibition of the MNK1/eIF4E pathway as a potential therapeutic target in patients with PCNSL.
Literatur
1.
Zurück zum Zitat Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J (2006) Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surg Neurol 66:503–506CrossRefPubMed Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J (2006) Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surg Neurol 66:503–506CrossRefPubMed
2.
Zurück zum Zitat Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477–480CrossRefPubMed Richter JD, Sonenberg N (2005) Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 433:477–480CrossRefPubMed
3.
Zurück zum Zitat Rousseau D, Gingras AC, Pause A, Sonenberg N (1996) The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415–2420PubMed Rousseau D, Gingras AC, Pause A, Sonenberg N (1996) The eIF4E-binding proteins 1 and 2 are negative regulators of cell growth. Oncogene 13:2415–2420PubMed
4.
Zurück zum Zitat Zimmer SG, DeBenedetti A, Graff JR (2000) Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20:1343–1351PubMed Zimmer SG, DeBenedetti A, Graff JR (2000) Translational control of malignancy: the mRNA cap-binding protein, eIF-4E, as a central regulator of tumor formation, growth, invasion and metastasis. Anticancer Res 20:1343–1351PubMed
5.
Zurück zum Zitat De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199CrossRefPubMed De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189–3199CrossRefPubMed
6.
Zurück zum Zitat Byrnes K, White S, Chu Q et al (2006) High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243:684–690 (discussion 691–692)CrossRefPubMed Byrnes K, White S, Chu Q et al (2006) High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243:684–690 (discussion 691–692)CrossRefPubMed
7.
Zurück zum Zitat Khoury T, Alrawi S, Ramnath N et al (2009) Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 10:58–66CrossRefPubMed Khoury T, Alrawi S, Ramnath N et al (2009) Eukaryotic initiation factor-4E and cyclin D1 expression associated with patient survival in lung cancer. Clin Lung Cancer 10:58–66CrossRefPubMed
8.
Zurück zum Zitat Ruggero D, Montanaro L, Ma L et al (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484–486CrossRefPubMed Ruggero D, Montanaro L, Ma L et al (2004) The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis. Nat Med 10:484–486CrossRefPubMed
9.
Zurück zum Zitat Wendel HG, De Stanchina E, Fridman JS et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337CrossRefPubMed Wendel HG, De Stanchina E, Fridman JS et al (2004) Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337CrossRefPubMed
10.
Zurück zum Zitat Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E–from translation to transformation. Oncogene 23:3172–3179CrossRefPubMed Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N (2004) eIF4E–from translation to transformation. Oncogene 23:3172–3179CrossRefPubMed
11.
Zurück zum Zitat Waskiewicz AJ, Flynn A, Proud CG, Cooper JA (1997) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16:1909–1920CrossRefPubMed Waskiewicz AJ, Flynn A, Proud CG, Cooper JA (1997) Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16:1909–1920CrossRefPubMed
12.
Zurück zum Zitat Pyronnet S (2000) Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 60:1237–1243CrossRefPubMed Pyronnet S (2000) Phosphorylation of the cap-binding protein eIF4E by the MAPK-activated protein kinase Mnk1. Biochem Pharmacol 60:1237–1243CrossRefPubMed
13.
Zurück zum Zitat Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350–5359CrossRefPubMed Scheper GC, Proud CG (2002) Does phosphorylation of the cap-binding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350–5359CrossRefPubMed
14.
Zurück zum Zitat Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24:6539–6549CrossRefPubMed Ueda T, Watanabe-Fukunaga R, Fukuyama H, Nagata S, Fukunaga R (2004) Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development. Mol Cell Biol 24:6539–6549CrossRefPubMed
15.
Zurück zum Zitat Wendel HG, Silva RL, Malina A et al (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232–3237CrossRefPubMed Wendel HG, Silva RL, Malina A et al (2007) Dissecting eIF4E action in tumorigenesis. Genes Dev 21:3232–3237CrossRefPubMed
16.
Zurück zum Zitat Bianchini A, Loiarro M, Bielli P et al (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29:2279–2288CrossRefPubMed Bianchini A, Loiarro M, Bielli P et al (2008) Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 29:2279–2288CrossRefPubMed
17.
Zurück zum Zitat Koga K, Todaka T, Morioka M et al (2001) Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248–6254PubMed Koga K, Todaka T, Morioka M et al (2001) Expression of angiopoietin-2 in human glioma cells and its role for angiogenesis. Cancer Res 61:6248–6254PubMed
18.
Zurück zum Zitat Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962–6970PubMed Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962–6970PubMed
19.
Zurück zum Zitat Wang S, Rosenwald IB, Hutzler MJ et al (1999) Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin’s lymphomas. Am J Pathol 155:247–255PubMed Wang S, Rosenwald IB, Hutzler MJ et al (1999) Expression of the eukaryotic translation initiation factors 4E and 2alpha in non-Hodgkin’s lymphomas. Am J Pathol 155:247–255PubMed
20.
Zurück zum Zitat Noske A, Lindenberg JL, Darb-Esfahani S et al (2008) Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 20:1409–1417PubMed Noske A, Lindenberg JL, Darb-Esfahani S et al (2008) Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 20:1409–1417PubMed
21.
Zurück zum Zitat Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV (1993) Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13:7358–7363PubMed Rosenwald IB, Lazaris-Karatzas A, Sonenberg N, Schmidt EV (1993) Elevated levels of cyclin D1 protein in response to increased expression of eukaryotic initiation factor 4E. Mol Cell Biol 13:7358–7363PubMed
22.
Zurück zum Zitat Topisirovic I, Ruiz-Gutierrez M, Borden KL (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64:8639–8642CrossRefPubMed Topisirovic I, Ruiz-Gutierrez M, Borden KL (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res 64:8639–8642CrossRefPubMed
23.
Zurück zum Zitat Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL (2005) eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3’UTR. J Cell Biol 169:245–256CrossRefPubMed Culjkovic B, Topisirovic I, Skrabanek L, Ruiz-Gutierrez M, Borden KL (2005) eIF4E promotes nuclear export of cyclin D1 mRNAs via an element in the 3’UTR. J Cell Biol 169:245–256CrossRefPubMed
24.
Zurück zum Zitat Soni A, Akcakanat A, Singh G et al (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782–1788CrossRefPubMed Soni A, Akcakanat A, Singh G et al (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782–1788CrossRefPubMed
Metadaten
Titel
Inhibition of eIF4E phosphorylation reduces cell growth and proliferation in primary central nervous system lymphoma cells
verfasst von
Daisuke Muta
Keishi Makino
Hideo Nakamura
Shigetoshi Yano
Mareina Kudo
Jun-ichi Kuratsu
Publikationsdatum
01.01.2011
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 1/2011
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-010-0233-6

Weitere Artikel der Ausgabe 1/2011

Journal of Neuro-Oncology 1/2011 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.